Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB304 for Décolleté Wrinkles (Pearl-2)
NCT06724900Phase 2Active, not recruiting
- Sponsor
- Krystal Biotech, Inc.
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Wrinkles comparing KB304 with Placebo (2 arms). Primary endpoint: Safety and tolerability of KB304 versus placebo at 4 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
KB304
03
Conditions
Wrinkles
Beyond the preview
Go deeper on NCT06724900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724900.